Global Leading Market Research Publisher QYResearch announces the release of its latest report "Medical Radioactive Microsphere Injection - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032" . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medical Radioactive Microsphere Injection market, including market size, share, demand, industry development status, and forecasts for the next few years. For interventional radiologists, hepatologists, oncologists, and healthcare administrators managing the complex therapeutic landscape of primary and metastatic liver malignancies, the ability to deliver targeted, high-dose radiation directly to tumor tissue while sparing surrounding healthy parenchyma represents a fundamental clinical imperative that directly determines treatment efficacy, toxicity profiles, and patient survival. Conventional external beam radiotherapy, while effective for many solid tumors, faces significant limitations in hepatic applications due to the liver's exquisite radiosensitivity and the risk of radiation-induced liver disease when meaningful tumoricidal doses are delivered. Medical radioactive microsphere injection addresses this critical therapeutic gap through interventional oncology techniques and selective internal radiation therapy that delivers Yttrium-90 microspheres directly to tumor vasculature via catheter-directed arterial administration. The global medical radioactive microsphere injection market was valued at US$ 112 million in 2025 and is projected to reach US$ 188 million by 2032, expanding at a robust CAGR of 7.8% during the forecast period—a trajectory that reflects accelerating adoption of liver cancer treatment and radioembolization therapy across comprehensive cancer centers and specialized interventional radiology practices worldwide . 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6085672/medical-radioactive-microsphere-injection Product Definition and Technology Architecture Medical radioactive microsphere injection is an advanced radioembolization therapy that utilizes vascular interventional techniques to deliver radionuclide-loaded microspheres—typically 20-60 microns in diameter—directly to tumor-supplying arteries or specific lesion sites. This liver cancer treatment modality exploits the differential blood supply distribution between hypervascular tumor tissue and normal hepatic parenchyma, enabling selective microsphere sequestration within tumor microvasculature. The Yttrium-90 microspheres deliver localized beta radiation (mean penetration 2.5 mm, maximum 11 mm) that kills tumor cells at close range while substantially sparing surrounding normal tissue. Medical radioactive microsphere injection provides dual therapeutic effects: internal radioembolization therapy and microvascular embolization, significantly improving local tumor control rates and extending patient survival. This selective internal radiation therapy is indicated for surgically unresectable primary hepatocellular carcinoma and colorectal cancer liver metastases . The technology landscape encompasses Yttrium-90 microsphere injection representing the predominant radioembolization therapy platform, Holmium-166 microsphere injection offering quantitative SPECT imaging capability for personalized dosimetry, and emerging radionuclide configurations addressing specific liver cancer treatment applications. The broader interventional oncology market context reinforces this growth trajectory, with global demand for medical radioactive microsphere injection expanding as clinical evidence supporting selective internal radiation therapy accumulates and multidisciplinary tumor boards increasingly incorporate Yttrium-90 microspheres into comprehensive liver cancer treatment algorithms. Industry Observation: Process Manufacturing with Stringent Regulatory Requirements The medical radioactive microsphere injection value chain is dominated by process manufacturing methodologies governed by exacting regulatory frameworks. Radionuclide production via neutron activation or cyclotron irradiation, microsphere fabrication with precise particle size control, and sterile formulation constitute core process manufacturing operations—requiring exacting control of specific activity, radionuclidic purity, and particle size distribution to achieve target radioembolization therapy dosimetry. Radiation safety protocols and cold-chain logistics represent critical selective internal radiation therapy considerations given the short physical half-life of Yttrium-90 microspheres (64.1 hours). Suppliers mastering integrated radiopharmaceutical manufacturing and distribution capture disproportionate value in regulated medical radioactive microsphere injection markets. Market Segmentation and Competitive Landscape The Medical Radioactive Microsphere Injection market is segmented as below: By Manufacturer: New Radiomedicine Technology, Grand Pharmaceutical Group Limited, YH Nu-Med, Boston Scientific, Sirtex Medical Limited, Terumo, ABK Biomedical, AtomVie, BWXT Medical Segment by Type: Holmium 166 Microsphere Injection | Yttrium 90 Microsphere Injection | Others Segment by Application: Cancer Treatment | Diagnosis | Others Market Drivers: Hepatocellular Carcinoma Burden and Multidisciplinary Adoption The medical radioactive microsphere injection market is propelled by the substantial global burden of hepatocellular carcinoma—the most common primary liver malignancy and a leading cause of cancer mortality worldwide. Many patients present with intermediate or advanced stage disease not amenable to curative resection or transplantation, creating significant demand for effective liver cancer treatment options. Radioembolization therapy with Yttrium-90 microspheres provides meaningful local tumor control and survival benefit in appropriately selected patients. Multidisciplinary tumor board adoption represents an equally powerful market catalyst. Selective internal radiation therapy has transitioned from experimental salvage therapy to established interventional oncology modality supported by prospective clinical trials demonstrating medical radioactive microsphere injection efficacy across multiple liver cancer treatment indications. Guideline inclusion by major hepatology and oncology societies further accelerates radioembolization therapy adoption. Technical Challenges: Dosimetry and Patient Selection Accurate medical radioactive microsphere injection requires sophisticated treatment planning. Pre-treatment angiography and technetium-99m macroaggregated albumin (99mTc-MAA) simulation assess pulmonary shunting and extrahepatic deposition risks essential for safe Yttrium-90 microspheres administration. Personalized radioembolization therapy dosimetry optimizes liver cancer treatment tumor dose while respecting normal tissue tolerance. Meticulous patient selection and multidisciplinary collaboration are essential for optimal selective internal radiation therapy outcomes. Strategic Outlook As hepatocellular carcinoma incidence persists globally, interventional oncology capabilities expand, and clinical evidence for radioembolization therapy accumulates, medical radioactive microsphere injection capable of delivering effective Yttrium-90 microspheres treatment, safe selective internal radiation therapy administration, and meaningful liver cancer treatment outcomes will sustain robust growth momentum. The market's 7.8% CAGR reflects strong demand across primary and metastatic liver cancer treatment applications, amplified by multidisciplinary adoption and the structural shift toward personalized interventional oncology. Suppliers delivering comprehensive medical radioactive microsphere injection solutions will capture sustained value through 2032. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp